经皮电神经刺激对STEMI患者缺血再灌注损伤及PCI术后二级预防的随机对照试验研究方案
针对急性心肌梗死再灌注损伤管理策略有限的问题,本研究设计多中心随机对照试验,纳入200例接受标准PCI的STEMI患者,按1:1随机分组,干预组接受3天TENS治疗,主要终点为心肌梗死面积,随访12周,旨在探索TENS作为非侵入性策略减轻再灌注损伤并促进二级预防的潜力。
要点
- TENS为安全无创、依从性好的干预,通过特定神经通路调节疼痛感知和自主神经活动。
- 研究纳入200例STEMI患者,1:1随机分组,所有患者接受标准PCI,干预3天。
- 主要终点为心肌梗死面积,次要终点包括炎症标志物、心肌损伤标志物、左心室功能、心率变异性及主要心血管事件,随访12周。
核心结论
- 本试验旨在探索TENS作为减轻STEMI患者再灌注损伤和增强二级预防的新型非侵入性策略,填补当前PCI术后管理的空白。
研究设计与样本
- 多中心随机对照试验,采用区域组随机化,200例接受再灌注的STEMI患者按1:1随机分为治疗组和对照组,所有患者接受标准PCI,干预3天,随访12周。
关键数值与推荐
- 主要终点为心肌梗死面积,通过系列心脏生物标志物测量评估。
- 次要终点包括炎症标志物、心肌损伤标志物、左心室功能、心率变异性及主要心血管事件。
临床怎么用
- 若试验证实有效,TENS可能成为STEMI患者PCI术后二级预防的新型非侵入性辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective strategies for managing ischemia-reperfusion injury in acute myocardial infarction remain limited, despite advances in reperfusion therapy. Transcutaneous electrical nerve stimulation (TENS), a safe and non-invasive intervention with good patient compliance, modulates pain perception and autonomic activity via specific neural pathways. These properties make it a promising candidate for integration into secondary prevention following percutaneous coronary intervention (PCI). Therefore, this randomized controlled trial investigates the potential of TENS as an innovative therapeutic approach in patients with ST-segment elevation myocardial infarction (STEMI). METHODS: This study was a multicenter randomized controlled trial designed to assess the effect of TENS in STEMI patients undergoing reperfusion. Using a randomization of district groups, 200 eligible patients will be randomized to either the treatment group or the control group (1:1 ratio), with all patients receiving standard PCI. The intervention will be administered for 3 days. The primary endpoint is myocardial infarct size (assessed by serial cardiac biomarker measurements), and secondary endpoints include inflammatory markers, myocardial injury markers, left ventricular function, heart rate variability, and major cardiovascular events. All patients will be followed for 12 weeks. DISCUSSION: This trial aims to explore TENS as a novel, non-invasive strategy for mitigating reperfusion injury and enhancing secondary prevention in STEMI patients, addressing a critical gap in current post-PCI management. TRIAL REGISTRATION: www.chictr.org.cn , Registration No. ChiCTR2400082515. Registered on 30 March 2024.
引用
- Zhang Z, Li M, Wang Y, et al. Transcutaneous electrical nerve stimulation (TENS) for ischemia-reperfusion injury and secondary prevention post-PCI in STEMI: study protocol for a randomized controlled trial. Trials. 2026. PMID: 41872950. doi:10.1186/s13063-026-09632-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。